← All drugs Report issue

nvp-ast487

Small moleculeexperimental

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

0

Phase 3

0

Phase 4

0

Mechanism of action

Tyrosine-protein kinase receptor RETINHIBITOR
RET inhibitor
Also potent against KDR, FLT4, KIT, and ABL1. Selective inhibitor of mutant FLT3.
- Proto-oncogene tyrosine-protein kinase receptor Ret (RET) ↗
Tyrosine-protein kinase receptor FLT3INHIBITOR
FLT3 inhibitor
Also potent against KDR, FLT4, KIT, and ABL1. Selective inhibitor of mutant FLT3.
- Receptor-type tyrosine-protein kinase FLT3 (FLT3) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1

Mol. weight: 529.57 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL574738 ↗

Also known as

ast-487
ast-487
nvp-ast487
nvp-ast487